Sundeep Agrawal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sundeep Agrawal has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Derek C. Angus
University of Pittsburgh, Pittsburgh, PA
1 shared publication - Donna R. Rivera
Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD
1 shared publication - Douglas R. Lowy
Laboratory of Cellular Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
1 shared publication - Elizabeth Garrett-Mayer
American Society of Clinical Oncology, Alexandria, VA
1 shared publication - Kald Abdallah
Bristol Myers Squibb
1 shared publication - Paul G. Kluetz
Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland
1 shared publication
Latest Publications
- 28 March 2022
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 28 (2) , 151-156
Clinical Evidence Generation During a Pandemic
Because of significant adaptations forced by the COVID-19 pandemic, resultant changes within health care delivery and clinical research introduced the potential for evaluation of novel evidence generation approaches in oncology. On July 26 and 27, 2021, the National Academies of Science, Engineering, and Medicine, National Cancer Policy Forum hosted a virtual workshop entitled “Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: A Workshop on Lessons Learned.” This workshop examined changes in cancer care and cancer research that occurred in response to the COVID-19 pandemic and considered lessons learned from that experience. The goal was to identify what changes could improve the delivery of high-quality cancer care and the conduct of cancer clinical trials in the postpandemic era, with an emphasis on health equity. How can we sustain the valuable lessons learned that might accelerate progress and enhance clinical evidence generation for patients and clinicians? In this overview, we discuss ways in which the COVID-19 experience has catalyzed research efficiencies as well as fostered a broader array of trial design and research methods that may facilitate improved cancer drug development during the pandemic and beyond.
- 28 March 2022
- Published by Wolters Kluwer Health in The Cancer Journal
- Vol. 28 (2) , 151-156
Clinical Evidence Generation During a Pandemic
Because of significant adaptations forced by the COVID-19 pandemic, resultant changes within health care delivery and clinical research introduced the potential for evaluation of novel evidence generation approaches in oncology. On July 26 and 27, 2021, the National Academies of Science, Engineering, and Medicine, National Cancer Policy Forum hosted a virtual workshop entitled “Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: A Workshop on Lessons Learned.” This workshop examined changes in cancer care and cancer research that occurred in response to the COVID-19 pandemic and considered lessons learned from that experience. The goal was to identify what changes could improve the delivery of high-quality cancer care and the conduct of cancer clinical trials in the postpandemic era, with an emphasis on health equity. How can we sustain the valuable lessons learned that might accelerate progress and enhance clinical evidence generation for patients and clinicians? In this overview, we discuss ways in which the COVID-19 experience has catalyzed research efficiencies as well as fostered a broader array of trial design and research methods that may facilitate improved cancer drug development during the pandemic and beyond.